{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T07:09:38Z","timestamp":1758265778727},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T00:00:00Z","timestamp":1491523200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1007\/s00774-017-0839-2","type":"journal-article","created":{"date-parts":[[2017,4,7]],"date-time":"2017-04-07T10:31:55Z","timestamp":1491561115000},"page":"336-343","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Monthly oral ibandronate 100\u00a0mg is as effective as monthly intravenous ibandronate 1\u00a0mg in patients with various pathologies in the MOVEST study"],"prefix":"10.1007","volume":"36","author":[{"given":"Hiroshi","family":"Hagino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoko","family":"Katsumata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Asao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumiko","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuo","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Mizunuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,4,7]]},"reference":[{"key":"839_CR1","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1185\/030079905X74862","volume":"21","author":"R Emkey","year":"2005","unstructured":"Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895\u20131903","journal-title":"Curr Med Res Opin"},{"key":"839_CR2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jbspin.2007.07.011","volume":"75","author":"P Hadji","year":"2008","unstructured":"Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Jt Bone Spine 75:303\u2013310","journal-title":"Jt Bone Spine"},{"key":"839_CR3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","volume":"65","author":"JY Reginster","year":"2006","unstructured":"Reginster JY, Adami S, Lakatos P, Greenwald M, Stepan JJ, Silverman SL, Christiansen C, Rowell L, Mairon N, Bonvoisin B, Drezner MK, Emkey R, Felsenberg D, Cooper C, Delmas PD, Miller PD (2006) Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2\u00a0year results from the MOBILE study. Ann Rheum Dis 65:654\u2013661","journal-title":"Ann Rheum Dis"},{"key":"839_CR4","first-page":"488","volume":"35","author":"JA Eisman","year":"2008","unstructured":"Eisman JA, Civitelli R, Adami S, Czerwinski E, Recknor C, Prince R, Reginster JY, Zaidi M, Felsenberg D, Hughes C, Mairon N, Masanauskaite D, Reid DM, Delmas PD, Recker RR (2008) Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol 35:488\u2013497","journal-title":"J Rheumatol"},{"key":"839_CR5","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-011-1773-0","volume":"23","author":"PD Miller","year":"2012","unstructured":"Miller PD, Recker RR, Reginster JY, Riis BJ, Czerwinski E, Masanauskaite D, Kenwright A, Lorenc R, Stakkestad JA, Lakatos P (2012) Efficacy of monthly oral ibandronate is sustained over 5\u00a0years: the MOBILE long-term extension study. Osteoporos Int 23:1747\u20131756","journal-title":"Osteoporos Int"},{"key":"839_CR6","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00198-011-1793-9","volume":"23","author":"G Bianchi","year":"2012","unstructured":"Bianchi G, Czerwinski E, Kenwright A, Burdeska A, Recker RR, Felsenberg D (2012) Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int 23:1769\u20131778","journal-title":"Osteoporos Int"},{"key":"839_CR7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1185\/030079908X253717","volume":"24","author":"ST Harris","year":"2008","unstructured":"Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237\u2013245","journal-title":"Curr Med Res Opin"},{"key":"839_CR8","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00198-008-0653-8","volume":"20","author":"A Cranney","year":"2009","unstructured":"Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291\u2013297","journal-title":"Osteoporos Int"},{"key":"839_CR9","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00198-013-2518-z","volume":"25","author":"PD Miller","year":"2014","unstructured":"Miller PD, Recker RR, Harris S, Silverman S, Felsenberg D, Reginster J, Day DM, Barr C, Masanauskaite D (2014) Long-term fracture rates seen with continued ibandronate treatment: pooled analysis of DIVA and MOBILE long-term extension studies. Osteoporos Int 25:349\u2013357","journal-title":"Osteoporos Int"},{"key":"839_CR10","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s00223-013-9734-6","volume":"93","author":"T Nakamura","year":"2013","unstructured":"Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, MOVER Study Group (2013) Clinical efficacy on fracture risk and safety of 0.5\u00a0mg or 1\u00a0mg\/month intravenous ibandronate versus 2.5\u00a0mg\/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int 93:137\u2013146","journal-title":"Calcif Tissue Int"},{"key":"839_CR11","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00223-014-9927-7","volume":"95","author":"H Hagino","year":"2014","unstructured":"Hagino H, Yoshida S, Hashimoto J, Matsunaga M, Tobinai M, Nakamura T (2014) Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study. Calcif Tissue Int 95:557\u2013563","journal-title":"Calcif Tissue Int"},{"key":"839_CR12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00774-015-0723-x","volume":"35","author":"M Ito","year":"2017","unstructured":"Ito M, Tobinai M, Yoshida S, Hashimoto J, Nakamura T (2017) Effect of monthly intravenous ibandronate injections on vertebral or non-vertebral fracture risk in Japanese patients with high-risk osteoporosis in the MOVER study. J Bone Miner Metab 35:58\u201364","journal-title":"J Bone Miner Metab"},{"key":"839_CR13","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00198-015-3175-1","volume":"26","author":"T Nakamura","year":"2015","unstructured":"Nakamura T, Ito M, Hashimoto J, Shinomiya K, Asao Y, Katsumata K, Hagino H, Inoue T, Nakano T, Mizunuma H, MOVEST Study Group (2015) Clinical efficacy and safety of monthly oral ibandronate 100\u00a0mg versus monthly intravenous ibandronate 1\u00a0mg in Japanese patients with primary osteoporosis. Osteoporos Int 26:2685\u20132693","journal-title":"Osteoporos Int"},{"key":"839_CR14","first-page":"251","volume":"26","author":"R Okazaki","year":"2016","unstructured":"Okazaki R (2016) Vitamin D insufficiency\/deficiency: its clinical significance and treatment. Clin Calcium 26:251\u2013258","journal-title":"Clin Calcium"},{"key":"839_CR15","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.bone.2008.10.052","volume":"44","author":"AI Sebba","year":"2009","unstructured":"Sebba AI, Emkey RD, Kohles JD, Sambrook PN (2009) Ibandronate dose response is associated with increases in bone mineral density and reductions in clinical fractures: results of a meta-analysis. Bone 44:423\u2013427","journal-title":"Bone"},{"key":"839_CR16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00223-010-9403-y","volume":"87","author":"PD Miller","year":"2010","unstructured":"Miller PD, Delmas PD, Huss H, Patel KM, Schimmer RC, Adami S, Recker RR (2010) Increases in hip and spine bone mineral density are predictive for vertebral antifracture efficacy with ibandronate. Calcif Tissue Int 87:305\u2013313","journal-title":"Calcif Tissue Int"},{"key":"839_CR17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s13318-014-0242-5","volume":"41","author":"K Nakai","year":"2016","unstructured":"Nakai K, Tobinai M, Hashimoto J, Iida S, Kawanishi T (2016) The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. Eur J Drug Metab Pharmacokinet 41:139\u2013147","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"839_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331\u2013337","journal-title":"J Bone Miner Metab"},{"key":"839_CR19","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00198-015-3464-8","volume":"27","author":"H Orimo","year":"2016","unstructured":"Orimo H, Yaegashi Y, Hosoi T, Fukushima Y, Onoda T, Hashimoto T, Sakata K (2016) Hip fracture incidence in Japan: estimates of new patients in 2012 and 25-year trends. Osteoporos Int 27:1777\u20131784","journal-title":"Osteoporos Int"},{"key":"839_CR20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00774-015-0717-8","volume":"34","author":"T Nakano","year":"2016","unstructured":"Nakano T, Yamamoto M, Hashimoto J, Tobinai M, Yoshida S, Nakamura T (2016) Higher response with bone mineral density increase with monthly injectable ibandronate 1\u00a0mg compared with oral risedronate in the MOVER study. J Bone Miner Metab 34:678\u2013684","journal-title":"J Bone Miner Metab"},{"key":"839_CR21","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1007\/s00198-011-1868-7","volume":"23","author":"AS Carmel","year":"2012","unstructured":"Carmel AS, Shieh A, Bang H, Bockman RS (2012) The 25(OH)D level needed to maintain a favorable bisphosphonate response is \u226533\u00a0ng\/ml. Osteoporos Int 23:2479\u20132487","journal-title":"Osteoporos Int"},{"key":"839_CR22","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s00223-009-9295-x","volume":"85","author":"M Ishijima","year":"2009","unstructured":"Ishijima M, Sakamoto Y, Yamanaka M, Tokita A, Kitahara K, Kaneko H, Kurosawa H (2009) Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int 85:398\u2013404","journal-title":"Calcif Tissue Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-017-0839-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-017-0839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-017-0839-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,5,5]],"date-time":"2018-05-05T20:48:27Z","timestamp":1525553307000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-017-0839-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,7]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["839"],"URL":"https:\/\/doi.org\/10.1007\/s00774-017-0839-2","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,7]]}}}